ERBB2 and neoplasm: Given our findings here that implicate Endo II in promoting trastuzumab response, but not that of lapatinib, it would be interesting to profile Endo II levels in tumor biopsies from the MA.31 clinical trial that compared trastuzumab and lapatinib for treatment of HER2+ patients with advanced breast cancer [51].